DOI QR코드

DOI QR Code

Relationship between the Lipid Accumulation Product Index and Alanine Aminotransferase in Korean Adult Men

한국 성인남성에서 Lipid Accumulation Product 지수와 Alanine Aminotransferase와의 관련성

  • Shin, Kyung-A (Department of Clinical Laboratory Science, Shinsung University)
  • 신경아 (신성대학교 임상병리과)
  • Received : 2017.10.16
  • Accepted : 2017.11.05
  • Published : 2017.12.31

Abstract

The LAP (lipid accumulation product) index is an indicator of excessive fat accumulation in combination with the fasting triglyceride concentration and waist circumference. This study examined the relationship between the LAP index and ALT (alanine aminotransferase) level and the effect of the LAP index on the ALT level. Cross-sectional studies were conducted on healthy adult males without a history of liver disease. From January 2015 to June 2017, 13,854 adults between 20 and 70 years of age, who underwent health screening at a general hospital in Gyeonggi-do, were enrolled in this study. The LAP index was calculated as [waist circumference (cm)-65]${\times}$[triglyceride (mmol/L)] for males. Serum ALT abnormalities were set at 40 IU/L or more in males. All subjects underwent measurements of the anthropometric indicators and physiological examinations. A significant increase in ALT with increasing LAP quintiles was observed (p<0.001). The LAP index correlated with ALT (r=0.238, p<0.001). Insulin (r=0.449, p<0.001) and HDL-cholesterol (r=-0.369, p<0.001) were strongly correlated with LAP. In addition, the LAP index is a factor affecting the ALT level (p<0.001). As the LAP index increased, the risk of an elevated ALT was higher (p<0.001). In conclusion, the LAP index was a predictor of an ALT elevation in Korean men.

References

  1. Kahn HS. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005; 5:26. https://doi.org/10.1186/1471-2261-5-26
  2. Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care. 2006;29(1):151-153. https://doi.org/10.2337/diacare.29.01.06.dc05-1805
  3. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006;2(4):367-373. https://doi.org/10.2174/1573399810602040367
  4. Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond). 2004;1(1):12. https://doi.org/10.1186/1743-7075-1-12
  5. Vieira BA, Sauer P, Marcadenti A, Piovesan CH. Association between LAP Index (Lipid Accumulation Product) and metabolic profile in hospitalized patients. Nutr Hosp. 2015;31(6):2771-2774.
  6. Carneiro Roriz AK, Santana Passos LC, Cunha de Oliveira C, Eickemberg M, de Almeida Moreira P, Ramos Sampaio L. Discriminatory power of indicators predictors of visceral adiposity evaluated by computed tomography in adults and elderly individuals. Nutr Hosp. 2014;29(6):1401-1407.
  7. Roriz AK, Passos LC, de Oliveira CC, Eickemberg M, Moreira Pde A, Sampaio LR. Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS One. 2014;9(7):e103499. https://doi.org/10.1371/journal.pone.0103499
  8. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab. 2003;284(6):E1065-1071. https://doi.org/10.1152/ajpendo.00442.2002
  9. Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, et al. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care. 2009;32(10):1916-1920. https://doi.org/10.2337/dc09-0412
  10. Zainuddin LR, Isa N, Muda WM, Mohamed HJ. The prevalence of metabolic syndrome according to various definitions and hypertriglyceridemic-waist in malaysian adults. Int J Prev Med. 2011;2(4):229-237.
  11. Amini M, Esmaillzadeh A, Sadeghi M, Mehvarifar N, Amini M, Zare M. The association of hypertriglyceridemic waist phenotype with type 2 diabetes mellitus among individuals with first relative history of diabetes. J Res Med Sci. 2011;16(2):156-164.
  12. Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G, et al. Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women. Metabolism. 2012;61(1):56-64. https://doi.org/10.1016/j.metabol.2011.05.017
  13. Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring). 2010;18(9):1836-1844. https://doi.org/10.1038/oby.2009.453
  14. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967. https://doi.org/10.1111/j.1572-0241.2003.07486.x
  15. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4): 1363-1370. https://doi.org/10.1002/hep.22109
  16. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285. https://doi.org/10.1111/j.1365-2036.2011.04724.x
  17. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006; 22(6):437-443. https://doi.org/10.1002/dmrr.666
  18. Despres JP, Cartier A, Cote M, Arsenault BJ. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med. 2008;40(7):514-523. https://doi.org/10.1080/07853890802004959
  19. Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci. 2008;53(5):1358-1363. https://doi.org/10.1007/s10620-008-0234-x
  20. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41(5):462-469. https://doi.org/10.1007/s00535-006-1790-5
  21. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48(2):449-457. https://doi.org/10.1002/hep.22350
  22. Ji BL, Li R, Zhang SH, Gong LL, Wang ZH, Ren W, et al. The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults. Nutr Res. 2012;32(8):581-587. https://doi.org/10.1016/j.nutres.2012.06.019
  23. Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14:49. https://doi.org/10.1186/s12986-017-0206-2
  24. Deurenberg-Yap M, Chew SK, Deurenberg P. Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes Rev. 2002;3(3):209-215. https://doi.org/10.1046/j.1467-789X.2002.00069.x
  25. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10:98. https://doi.org/10.1186/1471-230X-10-98
  26. Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z. Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2013;121(2):115-118. https://doi.org/10.1055/s-0032-1333261
  27. Mirmiran P, Bahadoran Z, Azizi F. Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. Endocrinol Metab (Seoul). 2014;29(4):443-449. https://doi.org/10.3803/EnM.2014.29.4.443
  28. Moon K, Sung SH, Chang YK, Park IK, Paek YM, Kim SG, et al. The association between Apolipoprotein E genotype and lipid profiles in healthy woman workers. J Prev Med Public Health. 2010;43(3):213-221. https://doi.org/10.3961/jpmph.2010.43.3.213
  29. Dobbelsteyn CJ, Joffres MR, MacLean DR, Flowerdew G. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. Int J Obes Relat Metab Disord. 2001;25(5):652-661. https://doi.org/10.1038/sj.ijo.0801582
  30. Tellechea ML, Aranguren F, Martinez-Larrad MT, Serrano-Rios M, Taverna MJ, Frechtel GD. Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. Diabetes Care. 2009;32(7):e85. https://doi.org/10.2337/dc08-2284
  31. Xia C, Li R, Zhang S, Gong L, Ren W, Wang Z, et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012; 66(9):1035-1038. https://doi.org/10.1038/ejcn.2012.83
  32. Shin KA. The clinical implications of hepatic enzymes in metabolically healthy obese men. Korean J Clin Lab Sci. 2017; 49(3):248-255. https://doi.org/10.15324/kjcls.2017.49.3.248
  33. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339-350. https://doi.org/10.1055/s-0028-1091978
  34. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50(1):204-210. https://doi.org/10.1016/j.jhep.2008.10.010
  35. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2): 183-190. https://doi.org/10.1038/nm1166